Medicare Enrolled

Dr. Moshe Levy, MD

Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
3410 WORTH ST, Dallas, TX 75246
2143701000
In practice since 2006 (19 years)
NPI: 1518059807 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Levy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Levy? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Levy

Dr. Moshe Levy is a medical oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Levy performed 35,628 Medicare services across 2,315 unique beneficiaries.

Between the years covered by Open Payments, Dr. Levy received a total of $4,760,026 from 68 pharmaceutical and/or device companies across 3284 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Levy is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 24% volume in TX$ $4,760,026 industry payments

Medicare Practice Summary

Medicare Utilization ↗
35,628
Medicare services
Top 24% in TX for medical oncology
2,315
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,875 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Darbepoetin injection (Aranesp) for anemia7,260$2$20
Pembrolizumab injection (Keytruda)6,900$43$136
Anti-nausea injection (fosaprepitant)4,800$0$5
Daratumumab injection (Darzalex)3,060$38$127
Paclitaxel chemotherapy injection3,037$0$8
Contrast dye for imaging (iodine-based)2,904$0$3
Dexamethasone injection (steroid)1,014$0$1
Comprehensive metabolic blood panel667$10$64
Blood draw (venipuncture)636$8$20
Complete blood count (CBC) with differential544$8$36
Anti-nausea injection (Aloxi/palonosetron)530$1$114
Injection, granisetron hydrochloride, 100 mcg510$0$24
Office visit, established patient (30-39 min)487$97$368
Lactate dehydrogenase (enzyme) level217$6$31
Complete blood count (CBC), automated196$6$34
Microscopic examination for white blood cells with manual cell count195$4$22
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less189$23$157
Measurement of immunoglobulin light chains188$17$60
Ferritin level test (iron stores)179$13$60
Office visit, established patient (20-29 min)174$62$250
Iron level test172$6$27
Iron binding capacity test172$9$35
Administration of chemotherapy into vein, 1 hour or less165$104$707
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg160$3$373
Immunoglobulin level test141$9$56
Injection of additional new drug or substance into vein135$12$108
Injection, carboplatin, 50 mg129$2$300
Reticulated (young) platelet measurement70$35$143
Injection, zoledronic acid, 1 mg68$7$431
Administration of additional new drug or substance into vein, 1 hour or less65$51$344
Basic metabolic blood panel60$8$49
Injection, diphenhydramine hcl, up to 50 mg59$1$7
Uric acid level test56$4$25
Office visit, established patient, complex (40-54 min)56$141$496
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less50$50$313
Drug injection, under skin or into muscle47$11$96
Hospital follow-up visit, moderate complexity47$62$247
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle42$58$211
New patient office visit, complex (60-74 min)33$162$709
Unclassified drugs33$1$8
Hospital follow-up visit, high complexity31$94$357
Ct scan of chest with contrast27$48$821
CT scan of abdomen and pelvis with contrast24$177$1,067
Administration of chemotherapy into vein, each additional hour24$23$161
Red blood count, automated test21$4$23
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour20$16$100
Infusion, normal saline solution , 1000 cc20$2$19
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion14$16$94
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.8% high complexity
86.7% medium
12.5% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$4,760,026
Total received (2018-2024)
Avg $680,004/year across 7 years
Top 0% in TX for medical oncology
68
Companies
3,284
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,134,503 (86.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$621,857 (13.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,666 (0.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$566,834
2023
$775,238
2022
$1,091,773
2021
$1,050,838
2020
$388,471
2019
$490,006
2018
$396,865

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Seagen Inc.
$1,032,891
Takeda Pharmaceuticals U.S.A., Inc.
$613,458
BeiGene USA, Inc.
$292,235
E.R. Squibb & Sons, L.L.C.
$286,754
Incyte Corporation
$258,499
Amgen Inc.
$192,555
AbbVie, Inc.
$175,501
Karyopharm Therapeutics Inc.
$170,316
AstraZeneca Pharmaceuticals LP
$152,037
Celgene Corporation
$142,258
SOBI, INC
$127,541
GlaxoSmithKline, LLC.
$123,611
Seattle Genetics, Inc.
$119,194
Dova Pharmaceuticals
$105,543
Janssen Biotech, Inc.
$89,006
ABBVIE INC.
$84,226
Epizyme, Inc.,
$78,741
Lilly USA, LLC
$73,523
Kite Pharma, Inc.
$70,453
GENZYME CORPORATION
$70,441
Sobi, Inc
$62,626
AbbVie Inc.
$52,122
JAZZ PHARMACEUTICALS INC.
$43,264
Ipsen Biopharmaceuticals, Inc
$40,397
PharmaEssentia USA Corporation
$31,167
NOVARTIS PHARMACEUTICALS CORPORATION
$30,063
Gilead Sciences, Inc.
$27,691
CTI BioPharma Corp.
$25,754
Novartis Pharmaceuticals Corporation
$24,616
Pharmacyclics LLC, An AbbVie Company
$22,291
Genmab U.S., Inc.
$21,390
Pharmacyclics LLC, an AbbVie Company
$16,627
PFIZER INC.
$15,219
Verastem, Inc.
$14,615
Janssen Scientific Affairs, LLC
$14,487
Genentech USA, Inc.
$14,270
Regeneron Pharmaceuticals, Inc.
$8,046
Adaptive Biotechnologies Corporation
$7,545
Agios Pharmaceuticals, Inc.
$4,859
Spectrum Pharmaceuticals Inc.
$4,502
Eli Lilly and Company
$3,632
MorphoSys, US Inc.
$2,721
Jazz Pharmaceuticals Inc.
$2,200
Blueprint Medicines Corporation
$2,136
Genentech, Inc.
$1,669
Geron Corporation
$1,600
Bayer HealthCare Pharmaceuticals Inc.
$1,195
BeiGene, Ltd.
$975
Astellas Pharma US Inc
$586
Janssen Global Services, LLC
$505
TG THERAPEUTICS, INC.
$450
Secura Bio, Inc.
$349
Rigel Pharmaceuticals, Inc.
$255
Aurobindo Pharma USA, Inc.
$250
SERVIER PHARMACEUTICALS LLC
$225
Pierre Fabre Pharmaceuticals, Inc.
$211
Stemline Therapeutics Inc.
$199
Daiichi Sankyo Inc.
$153
Emmaus Medical, Inc.
$92
ADC Therapeutics America, Inc.
$77
Acrotech Biopharma LLC
$47
RECORDATI_RARE_DISEASES_INC.
$40
Merck Sharp & Dohme LLC
$27
Legend Biotech USA Inc.
$25
Regeneron Healthcare Solutions, Inc.
$25
Mirati Therapeutics, Inc.
$21
Taiho Oncology, Inc.
$14
Acceleron Pharma, Inc.
$13
Top 3 companies account for 40.7% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · ALTUVIIIO · AYVAKIT · Aliqopa · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRUKINSA · Blincyto · CABLIVI · CALQUENCE · Copiktra · DARZALEX · DAURISMO · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EPKINLY · Endari · Epkinly · FARYDAK · Farydak · HEMANGEOL · Hemady · ICLUSIG · IMBRUVICA · INREBIC · Imbruvica · Inrebic · JAKAFI · JAYPIRCA · KEYTRUDA · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LYNPARZA · MONJUVI · NINLARO · Non-Covered Product · OJJAARA · ONUREG · OPDIVO · OXBRYTA · POLIVY · PROMACTA · PYRUKYND · Pomalyst · REBLOZYL · RETEVMO · RYTELO · Reblozyl · Revlimid · Rezlidhia · Rituxan · SARCLISA · SCEMBLIX · SPRYCEL · SYLVANT · TAGRISSO · TASIGNA · TAZVERIK · TECVAYLI · TIBSOVO · Tavalisse · Tazverik · Tibsovo · UKONIQ · VELCADE · VENCLEXTA · VONJO · VYNDAQEL · VYXEOS · Vanflyta · Venclexta · Vonjo · XGEVA · XOSPATA · XPOVIO · Xospata · Yescarta · ZEPZELCA · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (87%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for medical oncology in TX.

Equivalent to $13,360 per 100 Medicare services performed
Looking for a medical oncology in Dallas?
Compare medical oncologys in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
90
Per 100K population
3.5
County median income
$74,149
Nearest hospital
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Levy is a mixed practice specialist, with above-average Medicare volume (top 24% in TX), and high industry engagement (speaking/promotional, top 0%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Levy experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Levy performed 7,260 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Levy receive payments from pharmaceutical companies?
Yes. Dr. Levy received a total of $4,760,026 from 68 companies across 3,284 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Levy's costs compare to other medical oncologys in Dallas?
Dr. Levy's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Levy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →